Abstracts tagged "Osteoporosis and rheumatoid arthritis (RA)"

Abstract Number: 324 • 2017 ACR/ARHP Annual Meeting
The Predictors of the Efficacy of Denosumab, a Monoclonal Antibody to RANK Ligand, on Osteoporosis in Rheumatoid Arthritis Patients from Japanese Multicenter Study
Kyosuke Hattori¹, Yuji Hirano¹, Yasuhide Kanayama², Nobunori Takahashi³, Naoki Ishiguro³ and Toshihisa Kojima³, ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Although early intensive treatment has improved medication of rheumatoid arthritis (RA), treatment for osteoporosis (OP) in RA patient will be more important. Here, we…
Abstract Number: 327 • 2017 ACR/ARHP Annual Meeting
Association of Anti-Cyclic Citrullinated Peptide Seropositivity and Lean Mass Index with Low Bone Mineral Density in Patients with Rheumatoid Arthritis
Katherine D. Wysham¹, Dolores M. Shoback², Kashif Jafri¹, Sarah L. Patterson³, Gabriela Schmajuk⁴, John B. Imboden Jr.⁵ and Patricia P. Katz⁵, ¹University of California, San Francisco, San Francisco, CA, ²Medicine, San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ³Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ⁵Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Osteoporotic fractures are associated with high morbidity and mortality. Persons with rheumatoid arthritis (RA) have twice the risk of osteoporosis-related fracture than age-matched…
Abstract Number: 328 • 2017 ACR/ARHP Annual Meeting
Secular Trends in the Risk of Fragility Fracture Among Patients with Rheumatoid Arthritis: A General Population-Based Study
Sarah Keller¹, Marcy B. Bolster², Amar Oza³, Sharan K. Rai⁴, Leo Lu³, Yuqing Zhang⁵ and Hyon K. Choi⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The risk of osteoporotic (OP) fracture among patients with rheumatoid arthritis (RA) is higher than that of the general population. The worldwide incidence of…
Abstract Number: 330 • 2017 ACR/ARHP Annual Meeting
Change in Bone Mineral Density in Patients with Rheumatoid Arthritis: Minimal 10-Year Follow-up
Hiraku Motomura, Isao Matsushita, Toshihito Hiraiwa and Tomoatsu Kimura, Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: To investigate the long-term change in bone mineral density (BMD) in patients with rheumatoid arthritis (RA). Methods: In a longitudinal study of 40 patients…
Abstract Number: 327 • 2016 ACR/ARHP Annual Meeting
Drug Retention Rate of Oral Bisphosphonate in Patients with Rheumatoid Arthritis
Ji-Heh Park¹, Seung-Geun Lee¹, Eun-Kyoung Park², Hee-Sang Tag³ and Geun-Tae Kim⁴, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea, ⁴Kosin University College of Medicine, Busan, South Korea
Background/Purpose: As rheumatoid arthritis (RA) is a well-established risk factor for osteoporosis and compression fracture, non-adherence to bisphosphonate (BP) therapy in patients with RA can…
Abstract Number: 331 • 2016 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drug Use and the Risk of Non-Vertebral Osteoporotic Fractures in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Takefumi Furuya¹, Eisuke Inoue^1,2, Masanori Nakayama¹, Eiichi Tanaka¹, Katsunori Ikari¹, Ayako Nakajima³, Atsuo Taniguchi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Clinical Research and Development, National Center for Child Health and Development, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Previous U.S. and Canadian studies [1-3] have suggested that no significant associations exist between use of biologic disease-modifying anti-rheumatic drugs (DMARDs) and risk of…
Abstract Number: 343 • 2016 ACR/ARHP Annual Meeting
Correlation Between Metacarpal Cortical Bone Mineral Density Measured By Dual X-Ray Densitometry and Radiogrammetry on Early Arthritis Patients
Irene Llorente Cubas*¹, Leticia Merino-Meléndez², Ana M. Ortiz Garcia³, Saturnino González Ortega⁴, Eugenio Escolano⁵, Alberto Garcia-Vadillo⁶, Esther Vicente-Rabaneda², Rosario Garcia-Vicuña⁶, Isidoro Gonzalez-Alvaro³ and Santos Castañeda⁷, ¹Rheumatology, H.U La Princesa, Madrid, Spain, ²Rheumatology, H.U. La Princesa, Madrid, Spain, ³Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁴X-ray diagnosis, X-ray diagnosis, Hospital de La Princesa, Madrid, Spain, ⁵Radiology Department, H.U La Princesa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁷Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain
Background/Purpose: Low bone mass at metacarpal (MC) diaphysis measured by radiogrammetry (DXR) has been described as a poor prognostic factor in rheumatoid arthritis (RA). However,…
Abstract Number: 344 • 2016 ACR/ARHP Annual Meeting
Is Rheumatoid Arthritis a Risk Factor for Fractures: A Systematic Review of Observational Studies
Ambika Gupta¹, Stephanie Pipe², Tanveer Towheed³ and Tassos Anastassiades², ¹Internal Medicine, Queen's University, Kingston, ON, Canada, ²Queen's University, Kingston, ON, Canada, ³Dept of Medicine, Queen's University, Kingston, ON, Canada
Background/Purpose: Rheumatoid Arthritis (RA) is a known risk factor for osteoporosis. There are many factors that contribute to this increased risk, including the use of…
Abstract Number: 345 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Anti-Cyclic Citrullinated Peptide (anti-CCP) Levels and Bone Mineral Density (BMD) or Fragility Fracture in Patients with Rheumatoid Arthritis (RA)
Tien-Tsai Cheng^1,2, Yin-Chou Chen^1,2, Shan-Fu Yu^1,2, Han-Ming Lai^1,2, Ben Yu-Jih Su^1,2, Fu-Mei Su^2,3, Wen-Chan Chiu^1,2, Chung-Yuan Hsu^1,4, Jia-Feng Chen¹ and Chi-Hua Ko¹, ¹Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, ²Chang Gung University College of Medicine, Kaohsiung, Taiwan, ³Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, ⁴Division of Rheumatology, Allergy, and Immunology, Chang Gung University College of Medicine, Kaohsiung, Taiwan
Background/Purpose: To explore the relationship of anti-CCP levels with BMD or fragility fracture in patients with RA Methods: This is a prospective cross sectional study.…
Abstract Number: 354 • 2016 ACR/ARHP Annual Meeting
A Longitudinal Cohort Study of Denosmab and Bisphosphonate for Prevention of Vertebral Fracture in Glucocorticoid-Induced Osteoporosis in Japanese
Ikuko Tanaka¹, Mari Ushikubo², Keisuke Izumi², Kumiko Akiya³ and Hisaji Oshima³, ¹NAGOYA Rheumatology Clinic, Nagoya, Japan, ²Department of Rheumatology, National Tokyo Medical Center, Tokyo, Japan, ³Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan
Background/Purpose: In recent years, denosumab, a monoclonal antibody against RANKL, has been proven for effective treatment of primary osteoporosis. However, effects of denosmab for glucocorticoid-induced…
Abstract Number: 509 • 2016 ACR/ARHP Annual Meeting
Association of Anti-Citrullinated Protein Antibody Positivity and Titer Levels to Low Hand BMD, and the Consequence of Low Hand BMD on DAS28 (CRP) Remission in Established RA: Findings from a US Observational Cohort
H Ahmad¹, E Alemao¹, Z Guo¹, M Frits², Michael Weinblatt² and N A Shadick², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hand bone mineral density (BMD) loss is an independent predictor of radiographic joint progression,1 and a potential indicator of vertebral and non-vertebral fracture risk.2…
Abstract Number: 2986 • 2016 ACR/ARHP Annual Meeting
Trends and Determinants of Osteoporosis Prevention and Management in Patients with Rheumatoid Arthritis Compared to Osteoarthritis
Gulsen Ozen^1,2, Diane L. Kamen³, Ted R Mikuls², Frederick Wolfe⁴ and Kaleb Michaud^2,4, ¹Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Despite more aggressive treatment strategies and new biologic DMARDs, the prevalence of osteoporosis (OP) leading to fracture in RA remains high. It is unknown…
Abstract Number: 375 • 2015 ACR/ARHP Annual Meeting
RA May Not Confer Addition Risk of Osteoporosis in Male Patients – Results of Cohort Analysis and Literature Review
Khush Aujla¹, Javeria Bhawal¹, Katie Langley² and Vikas Majithia¹, ¹Division of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ²University of Mississippi Medical Center, Jackson, MS
Background/Purpose: Osteoporosis (OP) is a common disease and is increasingly being recognized in males. A number of underlying diseases including rheumatoid arthritis (RA) have been…
Abstract Number: 384 • 2015 ACR/ARHP Annual Meeting
Dental Treatments, Tooth Extraction, and Osteonecrosis at Jaw in Japanese Patients with Rheumatoid Arthritis; Results from the IORRA Cohort Study
Takefumi Furuya, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Oral health is an important issue for the patients with rheumatoid arthritis (RA) because many RA patients were treated with bisphosphonates and bisphosphate use…
Abstract Number: 579 • 2015 ACR/ARHP Annual Meeting
Methotrexate Does Not Influence 1-Year Bone Mineral Density in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Richard Koch¹, Thomas Barnetche², Adeline Ruyssen-Witrand¹, Alain Cantagrel¹, Arnaud Constantin³ and Yannick Degboé⁴, ¹Rheumatology Center, Purpan University Hospital, Toulouse, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Inserm U558, Rheumatology Center, Purpan University Hospital, Toulouse, France, ⁴Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with reduction of bone mineral density (BMD) and increased risk of peripheral and axial fractures. Methotrexate is the first-line…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].